2011
DOI: 10.1074/jbc.m110.212514
|View full text |Cite
|
Sign up to set email alerts
|

Role of YKL-40 in the Angiogenesis, Radioresistance, and Progression of Glioblastoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

17
237
2

Year Published

2013
2013
2021
2021

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 227 publications
(256 citation statements)
references
References 48 publications
17
237
2
Order By: Relevance
“…Preclinical studies and experimental models using glioma cells indicate a role of CHI3L1 in tumor dissemination and drug resistance (110). The ability of CHI3L1 to bind heparan sulfates allows its interaction with cell surface proteoglycan syndecan-1, resulting in VEGF production and enhanced angiogenesis in glioblastoma (110).…”
Section: Chi3l1 In Inflammation and Cancermentioning
confidence: 99%
“…Preclinical studies and experimental models using glioma cells indicate a role of CHI3L1 in tumor dissemination and drug resistance (110). The ability of CHI3L1 to bind heparan sulfates allows its interaction with cell surface proteoglycan syndecan-1, resulting in VEGF production and enhanced angiogenesis in glioblastoma (110).…”
Section: Chi3l1 In Inflammation and Cancermentioning
confidence: 99%
“…Despite increasing knowledge about the effects of radiation on biochemical pathways, the exact mechanisms of intrinsic radioresistance remain unclear. To date, it has been reported that a number of key cellular features appear to play a role in the development of intrinsic radioresistance, including overexpression of DNA repair proteins (8), modifications of signaling pathways (9), angiogenesis (10) and the presence of cancer stem cells (11).…”
Section: Introductionmentioning
confidence: 99%
“…[15][16][17] In many of these disorders, YKL-40 correlates with disease activity and its expression is believed to reflect distinct pathways in disease pathogenesis. [18][19][20] However, to date, the expression and biology of Brp-39/YKL-40 in the kidney, its roles in the pathogenesis of acute or other forms of kidney injury, and its utility as a biomarker for renal diseases have not been investigated.…”
mentioning
confidence: 99%